TET2 and chronic myelomonocytic leukemia: Homozygous and heterozygous mutations in TET2 gene are recurrent in hematopoietic malignancies besides CMML (frequency ranging from 30 to 60%), including myelodysplastic syndromes (20–35%), AML (12–34%) or lymphoid malignancies (2–33%) [85].